Company news
Sera Prognostics, Inc. news in 2021
Sera Prognostics, Inc.'s news releases, calls and decks from 2021, newest first.
SERA Prognostics added to NASDAQ Biotechnology Index
December 14, 2021
Sera Prognostics Announces Pricing For PreTRM® Test, The Only Broadly Validated Blood Test To Assess Risk Of Preterm Birth
December 1, 2021
Sera Prognostics Announces Publication Of Data Confirming The Performance Of The IBP4/SHBG Biomarkers In Diverse Non-U.S. Populations
November 30, 2021
Sera Prognostics Announces The Appointment Of Sandra A.J. Lawrence To The Sera Prognostics Board
November 29, 2021
Sera Prognostics Reports Third Quarter 2021 Financial Results
November 8, 2021
Sera Prognostics Announces The Appointment Of Zhenya Lindgardt To The Board
November 7, 2021
Sera Prognostics Appoints Woodrow Myers, MD, MBA As Advisor Of Public And Political Affairs
November 3, 2021
Sera Prognostics Announces Publication of the Clinical Validation of PreTRM® Threshold for Clinical Action
November 2, 2021
Sera Prognostics Announces Collaboration To Help Underserved Communities Make Informed Decisions About Prenatal Health
November 1, 2021
Sera Prognostics Announces Conference Call and Webcast of Third Quarter 2021 Financial Results on November 9
October 26, 2021
Sera Prognostics Appoints Dr. Paul Kearney as Chief Data Officer
September 27, 2021
Sera Prognostics to be Added to Russell 2000 Index
September 19, 2021
Sera Prognostics Appoints Dr. Michael R. Foley as Chief Medical Officer
September 14, 2021
Sera Prognostics Announces Publication of Health Economic Analysis Supporting PreTRM® Test-and-Treat Strategy to Improve Maternal and Infant Health
September 13, 2021
Sera Prognostics Reports Second Quarter 2021 Financial Results
August 29, 2021
Sera Prognostics’ PreTRM® Test and Treat Strategy Benefits Demonstrated by Results of Prospective, Randomized Controlled Intervention Trial Evaluating Clinical Utility
August 16, 2021
Sera Prognostics Announces Pricing of Initial Public Offering
July 13, 2021